Table 2.
Characteristics of the 1,023 subjects who underwent gastrectomy for non-metastatic Stage IB–IV gastric adenocarcinoma, stratified by adjuvant treatment.
| Characteristic | All subjects, n=1,023 |
No adjuvant therapy, n=583 |
Either chemotherapy OR radiation therapy, n=131 |
Chemotherapy AND radiation therapy, n=309 |
p-valueb | |
|---|---|---|---|---|---|---|
|
Age at diagnosis (median (IQR)) |
76.3 (71.6–81.0) |
78.8 (73.7–83.6) |
75.1 (69.9–79.0) |
73.0 (70.0–76.7) |
<0.0001 | |
| Gender (n, (%)) | 0.0503 | |||||
| Male | 561 (54.8) | 303 (52.0) | 71 (54.2) | 187 (60.5) | ||
| Female | 462 (45.2) | 280 (48.0) | 60 (45.8) | 122 ( 39.5) | ||
| Race (n, (%)) | 0.0811 | |||||
| White | 737 (72.0) | 419 (71.9) | 96 (73.3) | 222 (71.8) | ||
| Asian | 173 (16.9) | 93 (16.0) | 17 (13.0) | 63 (20.4) | ||
| Other (including black) | 113 (11.1) | 71 (12.2) | 18 (13.7) | 24 (7.8) | ||
| SES Quintile (n, (%)) | 0.0185 | |||||
| 0 | 220 (21.5) | 145 (24.9) | 23 (17.6) | 52 (16.8) | ||
| 1 | 214 (20.9) | 118 (20.2) | 33 (25.2) | 63 (20.4) | ||
| 2 | 197 (19.3) | 119 (20.4) | 17 (13.0) | 61(19.7) | ||
| 3 | 182 (17.8) | 91 (15.6) | 31 (23.7) | 60 (19.4) | ||
| 4 | 210 (20.5) | 110 (18.9) | 27 (20.6) | 73 (23.6) | ||
| Six month diagnosis block (n, (%)) | 0.1393 | |||||
| Early 2000 | 189 (18.5) | 118 (20.2) | 32 (24.4) | 39 (12.6) | ||
| Late 2000 | 160 (15.6) | 87 (14.9) | 19 (14.5) | 54 (17.5) | ||
| Early 2001 | 179 (17.5) | 105 (18.0) | 21 (16.0) | 53 (17.2) | ||
| Late 2001 | 148 (14.5) | 85 (14.6) | 19 (14.5) | 44 (14.3) | ||
| Early 2002 | 176 (17.2) | 95 (16.3) | 17 (13.0) | 64 (20.7) | ||
| Late 2002 | 171 (16.7) | 93 (16.0) | 23 (17.6) | 55 (17.8) | ||
| T categorya (n, (%)) | 0.0002 | |||||
| T1 or T2 | 705 (69.6) | 432 (74.6) | 77 (59.7) | 196 (64.3) | ||
| T3 or T4 | 308 (30.4) | 147 (25.4) | 52 (40.3) | 109 (35.7) | ||
| N categorya (n, (%)) | <0.0001 | |||||
| N0 | 294 (31.0) | 234 (43.5) | 21 (17.7) | 39 (13.4) | ||
| N1 | 453 (47.7) | 231 (42.9) | 60 (50.4) | 162 (55.5) | ||
| N2 or N3 | 202 (21.3) | 73 (13.6) | 38 (31.9) | 91 (31.2) | ||
| Gradea (n, (%)) | 0.0046 | |||||
| 1 or 2 | 329 (32.7) | 211 (36.8) | 32 (24.8) | 86 (28.3) | ||
| 3 or 4 | 677 (67.3) | 362 (63.2) | 97 (75.2) | 218 (71.7) | ||
| Charlson (n, (%)) | <0.0001 | |||||
| 0 | 575 (56.2) | 301 (51.6) | 90 (68.7) | 184 (59.6) | ||
| 1 | 273 (26.7) | 154 (26.4) | 23 (17.6) | 96 (31.1) | ||
| 2+ | 175 (17.1) | 128 (22.0) | 18 (13.7) | 29 (9.4) | ||
| Gastrectomy at teaching hospital (n, (%)) | 0.4688 | |||||
| Yes | 552 (54.0) | 306 (52.5) | 76 (58.0) | 170 (55.0) | ||
| No | 471 (46.0) | 277 (47.5) | 55 (42.0) | 139 (45.0) | ||
|
Distance to RT facilitya (miles, median (IQR)) |
5.1 (2.5–12.2) |
5.2 (2.5–12.0) |
5.0 (2.5–13.5) |
5.3 (2.9–13.1) |
0.7486 | |
| SEER Region (n, (%)) | 0.3798 | |||||
| Northeast | 277 (27.1) | 160 (27.4) | 35 (26.7) | 82 (26.5) | ||
| South | 134 (13.1) | 85 (14.6) | 15 (11.5) | 34 (11.0) | ||
| Midwest | 106 (10.4) | 63 (10.8) | 17 (13.0) | 26 (8.4) | ||
| West | 506 (49.5) | 275 (47.2) | 64 (48.9) | 167 (54.1) | ||
a
Sample size does not add to 1,023 due to missing responses.
b
Comparison across treatment groups.
Abbreviations: SES=socioeconomic status, T=tumor, N=lymph node, RT=radiation therapy.